Abstract
Despite advances in wound care, many wounds never heal and become chronic problems that result in significant morbidity and mortality to the patient. Cellular therapy for cutaneous wounds has recently come under investigation as a potential treatment modality for impaired wound healing. Bone marrow-derived mesenchymal stem cells (MSCs) are a promising source of adult progenitor cells for cytotherapy as they are easy to isolate and expand and have been shown to differentiate into various cell lineages. Early studies have demonstrated that MSCs may enhance epithelialization, granulation tissue formation, and neovascularization resulting in accelerated wound closure. It is currently unclear if these effects are mediated through cellular differentiation or by secretion of cytokines and growth factors. This review discusses the proposed biological contributions of MSCs to cutaneous repair and their clinical potential in cell-based therapies.
Highlights
Chronic wounds are a cause of significant morbidity and mortality and pose a large financial burden on the healthcare system
WORK The possible benefits of mesenchymal stem cells (MSCs)-based therapy in the clinically important area of chronic wounds have been demonstrated in numerous studies
The International Society for Cellular Therapy has published minimum criteria to define human MSCs, significant heterogeneity certainly exists within this population (Dominici et al, 2006)
Summary
Chronic wounds are a cause of significant morbidity and mortality and pose a large financial burden on the healthcare system. Local delivery of MSCs significantly increased granulation tissue formation and decreased wound healing time in leptin receptor-deficient db/db diabetic mice compared to those treated with either PBS or non-cell typespecific bone marrow aspirate (Javazon et al, 2007). Injection of primary bone marrow cells into the wound edge followed by topical application of cultured MSCs resulted in the complete closure of three chronic wounds which had failed traditional therapy including autologous skin grafting (Badiavas and Falanga, 2003). MSCs ENHANCE WOUND HEALING BY DIFFERENTIATION INTO EPIDERMAL CELLS There is data to suggest that MSCs mobilize from the bone marrow niche and traffic to ischemic tissue via the peripheral circulation in response to cytokine signaling (Hamou et al, 2009).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
